Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.00767
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA


Related search